Pharma raises its bet on biotech

The construction of the Erie Canal is one of the most ambitious infrastructure projects in American history. But its most influential legacy is not the waterway itself, it is how it was paid for. Hosts Gillian Tett and Robin Wigglesworth speak with financial historian Richard Syl ...  Show more

Jesse Livermore was a legendary trader who made and lost several fortunes in the early 20th century, most famously by shorting the Wall Street crash of 1929. His early life was immortalised in the roman à clef Reminiscences of a Stock Operator by Edwin Lefèvre, and his trading in ...  Show more

Apple & Amazon the latest big tech names to report results. The headlines from the company conference calls, and what top tech analyst Gene Munster sees in store for the group. Plus Eli Lilly jumping as its obesity drug sales soar. How the company is moving the needle in the w ...

(Bloomberg) -- Taking Stock with Kathleen Hays and Pimm Fox. \u0010 \u0010GUEST: \u0010Cynthia Koons \u0010Health Care Reporter \u0010Bloomberg Editorial \u0010on Pfizer beating out rivals to buy biopharmaceutical company, Medivation, and its blockbuster cancer drug for $14 billi ...  Show more

Laura Chico, Biotechnology Research Analyst at Wedbush Securities and Bloomberg News US Deals Team Leader Matthew Monks share their thoughts on the Bristol Myers acquisition Karuna Therapeutics. John Mowrey, CIO at NFJ Investment Group, explains where to find value in the markets ...  Show more

Bloomberg’s Caroline Hyde and Ed Ludlow discuss Electronic Arts’ agreement to be sold in a record-breaking leveraged buyout. Plus, Huawei plans to ramp up production of its most advanced AI chips in a bid to take market share from Nvidia. And Peloton is preparing to launch new AI ...  Show more